AC Immune SAのEBITDA margin
AC Immune SAのEBITDA marginは何ですか。
AC Immune SAのEBITDA marginは293.05%です。
EBITDA marginの定義は何ですか。
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
NASDAQのセクタHealth CareにおけるEBITDA marginの企業と比べるAC Immune SA
AC Immune SAは何をしますか。
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
AC Immune SAと類似のebitda margin
- Western Asset Inflation-Linked Income FundのEBITDA marginは279.93%です。
- Banimmo SAのEBITDA marginは282.01%です。
- Nuveen New Jersey Municipal Value FundのEBITDA marginは284.57%です。
- Wellness and Beauty SolutionsのEBITDA marginは287.70%です。
- BP Prudhoe Bay Royalty TrustのEBITDA marginは288.86%です。
- First Trust Dynamic Europe Equity Income FundのEBITDA marginは289.58%です。
- AC Immune SAのEBITDA marginは293.05%です。
- Norvista CapitalのEBITDA marginは294.05%です。
- abrdn Japan Equity Fund IncのEBITDA marginは294.71%です。
- Allied Hotel PropertiesのEBITDA marginは298.57%です。
- Gabelli Healthcare & WellnessRx TrustのEBITDA marginは301.04%です。
- Nuveen California AMT-Free Quality Municipal Income FundのEBITDA marginは301.50%です。
- Gabelli Global Small and Mid Cap Value TrustのEBITDA marginは301.61%です。